Cannabis Pharmaceuticals Market Expected to Reach $111 Billion by 2032

A $111 Billion Opportunity Takes Shape

The cannabis pharmaceuticals sector is poised for explosive growth that would transform it from a niche market into a major global industry. According to a comprehensive May 2026 report from ResearchAndMarkets.com, the global cannabis pharmaceuticals market—valued at approximately $4.7 billion in 2025—is projected to reach $111.1 billion by 2032, representing a staggering compound annual growth rate (CAGR) of 57.1%.

To put that growth rate in perspective, it exceeds even the early expansion trajectories of streaming media and electric vehicles. If realized, the cannabis pharma market would roughly triple from its current size every two years for the next six years straight.

What's Driving This Growth

Several converging factors explain why analysts are forecasting such extraordinary expansion.

Federal Rescheduling Opens Research Floodgates

The DOJ's April 2026 decision to place state-licensed medical cannabis in Schedule III is perhaps the single largest catalyst. Under Schedule I classification, universities and pharmaceutical companies faced enormous bureaucratic and financial barriers to conducting cannabis research. Schedule III removes many of those obstacles, allowing established pharmaceutical companies to invest in cannabinoid drug development with significantly reduced regulatory friction.

The DEA has confirmed it will open new registration forms for medical cannabis cultivators, manufacturers, testing laboratories, and distributors in the coming weeks—creating the infrastructure for pharmaceutical-grade cannabis production at scale.

The Opioid Crisis Demands Alternatives

Healthcare systems worldwide are actively seeking non-addictive pain management solutions. Cannabis-based pharmaceuticals have demonstrated efficacy for chronic pain conditions without the dependency risks associated with opioid medications. As insurance companies and healthcare providers increasingly recognize cannabinoid therapies, prescription adoption rates are accelerating.

Expanding Global Legalization

Beyond North America, medical cannabis frameworks are expanding across Europe, with Germany, the UK, and France all developing or expanding patient access programs. Asia-Pacific markets including Thailand and Australia are also building regulatory infrastructure for medical cannabis, creating addressable market expansion that didn't exist five years ago.

Key Market Segments

The cannabis pharmaceuticals market encompasses several distinct product categories, each with its own growth trajectory:

Prescription Cannabinoid Drugs: FDA-approved medications like Epidiolex (CBD-based epilepsy treatment) and Marinol (synthetic THC for nausea and appetite) represent the most established segment, with growing prescription volumes and potential new indications.

Standardized Cannabis Extracts: Pharmaceutical-grade extracts with precise cannabinoid ratios for specific conditions, manufactured under GMP standards and distributed through pharmacy channels.

Novel Cannabinoid Formulations: Next-generation delivery systems including transdermal patches, sublingual strips, nanosized emulsions, and metered-dose inhalers designed for clinical precision and bioavailability.

Cannabinoid-Based Biologics: Emerging research into synthetic cannabinoids and receptor-targeted therapies that could treat conditions from inflammatory disorders to certain cancers.

Major Players Positioning for Growth

The report highlights several companies at the forefront of cannabis pharmaceutical development:

AbbVie — Already marketing Marinol and investing in expanded cannabinoid research pipelines.

Aurora Cannabis — Transitioning from recreational market pressures to medical-focused pharmaceutical operations with GMP-certified facilities.

Canopy Growth — Leveraging its research partnerships and biopharmaceutical subsidiary to develop prescription cannabinoid products.

Bausch Health — Exploring cannabinoid applications for neurological and gastrointestinal conditions through its specialty pharma portfolio.

GW Pharmaceuticals (Jazz Pharmaceuticals) — Developer of Epidiolex, with additional cannabinoid drugs in clinical trials targeting multiple sclerosis spasticity and autism spectrum disorder.

Why Projections Vary

Not all analysts agree on the exact figure. Multiple research firms have published varying projections for 2032:

• ResearchAndMarkets: $111.1 billion (57.1% CAGR)
• Precedence Research: $211.7 billion (58.3% CAGR)
• SkyQuest Technology: $145.7 billion (varying methodology)

The discrepancies reflect different assumptions about regulatory timelines, market penetration rates, and which product categories qualify as "cannabis pharmaceuticals." Some broader definitions include wellness CBD products, while narrower definitions focus exclusively on prescription medications.

Regardless of which projection proves most accurate, the directional consensus is clear: the cannabis pharmaceutical sector is entering a period of unprecedented expansion.

Challenges and Risk Factors

Despite bullish projections, significant headwinds remain:

Regulatory Uncertainty: The June 29, 2026 DEA hearing on broader rescheduling could introduce new restrictions or unexpected regulatory frameworks. Meanwhile, lawsuits from Indiana, Nebraska, and Louisiana attorneys general seeking to block the Schedule III move create legal uncertainty.

Clinical Trial Costs: Bringing cannabinoid drugs through Phase I-III trials still requires hundreds of millions of dollars and years of development time. Most cannabis companies lack the capital reserves of traditional pharma.

Patent Complexity: The natural origin of cannabinoids makes patent protection challenging compared to synthetic pharmaceuticals. Companies must rely on formulation, delivery system, and method-of-use patents rather than compound patents.

Insurance Coverage: Until major health insurers routinely cover cannabinoid prescriptions, patient adoption will remain constrained by out-of-pocket costs.

Investment Implications

For cannabis investors, the pharmaceuticals segment represents a potential value creation engine that could decouple from the volatile dynamics of the recreational market. Companies with GMP-certified facilities, active clinical trial programs, and pharmaceutical partnerships may command premium valuations as the market matures.

The sector also offers a potential acquisition pathway, with traditional Big Pharma companies likely to acquire cannabis pharmaceutical assets rather than build capabilities from scratch—a pattern already emerging with Jazz Pharmaceuticals' acquisition of GW Pharmaceuticals.

The Road to $111 Billion

The cannabis pharmaceuticals market won't grow linearly. The next 18 months are likely to see the highest percentage growth rates as regulatory barriers fall and institutional capital floods in. By 2028-2029, the market should reach critical mass with multiple approved medications, established insurance coverage pathways, and mature manufacturing supply chains.

For an industry that spent decades fighting for basic legitimacy, the prospect of becoming a $111 billion pharmaceutical market represents nothing less than a complete transformation—from counterculture to clinical standard of care.